Inhibrx Reports First Quarter 2025 Financial Results
- Investing.com
- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Inhibrx Biosciences Inc (INBX)
"Inhibrx Biosciences Inc stock price live, this page displays NASDAQ INBX stock exchange data. View the INBX premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Inhibrx Biosciences Inc real time stock price chart below.
What Is the Inhibrx Biosciences Inc Stock Price Today?
The Inhibrx Biosciences Inc stock price today is 12.86.
What Is the Stock Symbol for Inhibrx Biosciences Inc?
The stock symbol for Inhibrx Biosciences Inc is ""INBX.""
What Stock Exchange Does Inhibrx Biosciences Inc Trade On?
Inhibrx Biosciences Inc is listed and trades on the NASDAQ stock exchange.
Is Inhibrx Biosciences Inc a Good Stock to Buy?
Determining whether Inhibrx Biosciences Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the INBX quote. (ISIN: US45720N1037)"
What Is the Inhibrx Biosciences Inc Stock Price Today?
The Inhibrx Biosciences Inc stock price today is 12.86.
What Is the Stock Symbol for Inhibrx Biosciences Inc?
The stock symbol for Inhibrx Biosciences Inc is ""INBX.""
What Stock Exchange Does Inhibrx Biosciences Inc Trade On?
Inhibrx Biosciences Inc is listed and trades on the NASDAQ stock exchange.
Is Inhibrx Biosciences Inc a Good Stock to Buy?
Determining whether Inhibrx Biosciences Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the INBX quote. (ISIN: US45720N1037)"
NASDAQ
Currency in USD
12.86
+0.32(+2.55%)
Closed·
After Hours
13.50+0.64(+4.98%)
·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
12.25
12.93
52 wk Range
10.80
18.95
INBX Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
INBX is not included in our AI-picked strategies. See which stocks are.
Review Strategies
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
12.2512.93
52 wk Range
10.8018.95
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
INBX Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Neutral
Price Target
12.00
Downside
-6.69%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
- Inhibrx CEO buys shares worth over $629k
- Investing.com
- Inhibrx Reports First Quarter 2025 Financial Results
- Investing.com
- Inhibrx reports promising ozekibart trial results
- Investing.com
- Inhibrx secures $150 million credit facility
- Investing.com
Inhibrx Biosciences Inc Company Profile
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck squamous cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, and urothelial cell carcinoma. Inhibrx Biosciences, Inc. was incorporated in 2024 and is based in La Jolla, California.
Inhibrx Biosciences Inc SWOT Analysis
Pipeline Promise | Explore Inhibrx's lead candidates ozekibart and INBRX-106, currently in pivotal trials for rare cancers and potential breakthrough treatments |
Financial Fortitude | Delve into Inhibrx's robust cash position of $226.9 million, bolstered by Sanofi's $2.2 billion deal, providing runway for ongoing clinical trials |
Market Valuation | Analysts suggest fair value around $13.49 per share, combining cash position and platform value. JMP Securities maintains "Market Perform" rating |
Strategic Alliances | Learn how Sanofi's partnership and 8% equity stake validate Inhibrx's platform technology and open doors for future collaborations |
Compare INBX to Peers and Sector
Metrics to compare | INBX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipINBXPeersSector | |
|---|---|---|---|---|
P/E Ratio | 0.1x | −0.5x | −0.4x | |
PEG Ratio | 0.00 | 0.00 | 0.00 | |
Price/Book | 2.0x | 1.6x | 2.6x | |
Price / LTM Sales | 930.8x | 10.5x | 2.9x | |
Upside (Analyst Target) | −4.3% | 296.0% | 53.5% | |
Fair Value Upside | Unlock | −4.7% | 9.5% | Unlock |
Analyst Ratings
0 Buy
2 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Neutral
Analysts 12-Month Price Target:
Average 12.00
(-6.69% Downside)
Earnings
Latest Release
May 14, 2025
EPS / Forecast
-2.80 / -1.41
Revenue / Forecast
-- / --
FAQ
What Is the Inhibrx Biosciences (INBX) Stock Price Today?
The Inhibrx Biosciences stock price today is 12.86
What Stock Exchange Does Inhibrx Biosciences Trade On?
Inhibrx Biosciences is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Inhibrx Biosciences?
The stock symbol for Inhibrx Biosciences is "INBX."
What Is the Inhibrx Biosciences Market Cap?
As of today, Inhibrx Biosciences market cap is 181.53M.
What Is Inhibrx Biosciences's Earnings Per Share (TTM)?
The Inhibrx Biosciences EPS (TTM) is 112.91.
From a Technical Analysis Perspective, Is INBX a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Inhibrx Biosciences Stock Split?
Inhibrx Biosciences has split 0 times.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.